COST-EFFECTIVENESS ANALYSIS OF ORAL SEMAGLUTIDE AS THE SECOND-LINE AND THIRD-LINE TREATMENT FOR TYPE 2 DIABETES PATIENT

被引：0
|
作者：
Tan, E. C. H. [1 ]
Yang, M. C. [2 ]
机构：
[1] China Med Univ, Dept Hlth Serv Adm, Taichung, Taiwan
[2] Natl Taiwan Univ, Taipei, Taiwan
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE15
引用
收藏
页码：S52 / S53
页数：2
相关论文
共 50 条
  • [41] Cost-Effectiveness of Saxagliptin Compared With Glibenclamide as a Second-Line Therapy Added to Metformin for Type 2 Diabetes Mellitus in Ethiopia
    Bekele, Mengistu
    Norheim, Ole Frithjof
    Hailu, Alemayehu
    MDM POLICY & PRACTICE, 2021, 6 (01)
  • [42] Cost-Effectiveness of Sorafenib for Second-Line Treatment of Advanced Renal Cell Carcinoma
    Hoyle, Martin
    Green, Colin
    Thompson-Coon, Jo
    Liu, Zulian
    Welch, Karen
    Moxham, Tiffany
    Stein, Ken
    VALUE IN HEALTH, 2010, 13 (01) : 55 - 60
  • [43] Cost-effectiveness analysis of second-line tyrosine kinase inhibitor treatment for chronic myelogenous leukemia
    Whalen, John
    Stillman, Ipek
    Ambavane, Apoorva
    Felber, Eugene
    Makenbaeva, Dinara
    Bolinder, Bjorn
    JOURNAL OF MEDICAL ECONOMICS, 2016, 19 (05) : 445 - 461
  • [44] Cost-effectiveness analysis of nivolumab and apatinib in third-line gastric cancer therapy.
    Yuan, Jiajia
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [45] COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB IN COMBINATION WITH LENVATINIB FOR THE TREATMENT OF ADVANCED SECOND-LINE ENDOMETRIAL CANCER
    Yfantopoulos, N.
    Gountas, I
    Skroumpelos, A.
    Theiakos, K.
    Economou, O.
    Karokis, A.
    VALUE IN HEALTH, 2024, 27 (12) : S113 - S113
  • [46] Cost-effectiveness analysis of pazopanib in second-line treatment of advanced soft tissue sarcoma in Spain
    G. Villa
    L. J. Hernández-Pastor
    M. Guix
    J. Lavernia
    M. Cuesta
    Clinical and Translational Oncology, 2015, 17 : 24 - 33
  • [47] Cost-effectiveness analysis of pazopanib in second-line treatment of advanced soft tissue sarcoma in Spain
    Villa, G.
    Hernandez-Pastor, L. J.
    Guix, M.
    Lavernia, J.
    Cuesta, M.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2015, 17 (01): : 24 - 33
  • [48] Cost-effectiveness analysis of nivolumab in the second-line treatment for advanced esophageal squamous cell carcinoma
    Zhang, Peng-Fei
    Xie, Dan
    Li, Qiu
    FUTURE ONCOLOGY, 2020, 16 (17) : 1189 - 1198
  • [49] Cost-effectiveness of Pembrolizumab as a Second-Line Therapy for Hepatocellular Carcinoma
    Chiang, Chi-leung
    Chan, Sik-kwan
    Lee, Shing-fung
    Wong, Irene Oi-ling
    Choi, Horace Cheuk-wai
    JAMA NETWORK OPEN, 2021, 4 (01)
  • [50] Cost-effectiveness of pembrolizumab in second-line advanced bladder cancer
    Sarfaty, Michal
    Hall, Peter
    Chan, Kelvin K.
    Virik, Kiran
    Leshno, Moshe
    Gordon, Noa
    Moore, Assaf
    Neiman, Victoria
    Rosenbaum, Eli
    Goldstein, Daniel A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
12345